Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and transactions involving the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director disclosures rather than financial performance metrics.
Material Changes
The following specific transactions regarding share interests were reported:
- Director Acquisition: On April 9, 2003, Director Mr. J D Coombe acquired 20 Ordinary Shares (10 via personal contribution and 10 via company matching) under the ShareReward Plan at a price of £12.42 per share.
- Trust Transfers: On April 4, 2003, the SmithKline Beecham Employee Benefit Trust transferred 37,964 Ordinary Shares to participants of the 1991 Share Option Plan.
- Trust Sales: On April 2, 2003, the Trust sold 225 Ordinary Shares at a price of £11.65 per share.
- Trust Corrections: On April 4, 2003, 101 Ordinary Shares were transferred back into the Trust following an incorrect transfer to a participant in the Mid Term Incentive Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of share ownership changes.
Key Facts for Investor Verification
- Verify the total number of shares held by Director Mr. J D Coombe following the April 9, 2003 acquisition.
- Confirm the impact of the 37,964 shares transferred from the Employee Benefit Trust on the company's outstanding share count.
- Note the discrepancy in share prices between the Trust sale (£11.65) and the Director's acquisition (£12.42) within the same week.